Login to Your Account



Talon Doses First Patient in Marqibo Phase III ALL Trial

By Peter Winter
BioWorld Insight Editor

Monday, June 4, 2012
Just over a month after the FDA's Oncologic Drugs Advisory Committee (ODAC) voted 7 to 4, with two abstentions, that Marqibo (vincristine sulfate liposome injection) demonstrated a favorable risk-benefit profile as a third-line treatment for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia, Talon Therapeutics Inc. reported the enrollment and dosing of the first patient.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription